ForPatients
by Roche

ObesityType 2 Diabetes Mellitus

A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes

Trial Status	Trial Runs In	Trial Identifier
Recruiting	1 Country	NCT07843485 2026-526189-25-00 CC46369

The information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc., and has not been edited.

Official Title:

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Once Weekly Petrelintide vs. Placebo in Participants With Overweight or Obesity and Type 2 Diabetes

Trial Summary:

This study will evaluate the efficacy and safety of petrelintide compared with placebo, in conjunction with a reduced-calorie diet and increased physical activity, for weight management in participants living with overweight or obesity and with Type 2 Diabetes (T2D).

Hoffmann-La Roche	Phase 3
Sponsor	Phase

NCT07843485 2026-526189-25-00 CC46369
Trial Identifiers

Eligibility Criteria:

Gender	Age	Healthy Volunteers
All	#18 Years	No

Inclusion Criteria:

- Participants with BMI # 27 kg/m²
- T2D diagnosis as per World Health Organization (WHO) classification (or other locally applicable standards) with HbA1c # 6.5% to # 10% (48-86 mmol/mol), measured by the central laboratory at screening

© 2022 F. Hoffmann-La Roche Ltd

- Stable treatment with either diet and exercise alone, basal insulin, or selected oral glucose-lowering agents, for at least 90 days prior to and during screening
- History of at least one self-reported unsuccessful dietary effort to lose body weight

Exclusion Criteria:

- History or presence of proliferative diabetic retinopathy, or diabetic macular edema
- Current or previous treatment with petrelintide or any other amylin analog

© 2022 F. Hoffmann-La Roche Ltd